Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 7/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4053495 | 1.00 | KMT2A (0.41) | KMT2AMEN1EPHX1CNR2ACHE | |
| SCHEMBL1536750 | 0.98 | KMT2A (0.42) | KMT2AMEN1EPHX1CNR2ACHE | |
| SCHEMBL19640034 | 0.95 | EPHX1 (0.42) | KMT2AMEN1EPHX1ACHERAB9A | |
| SCHEMBL2722735 | 0.92 | EPHX1 (0.44) | EPHX1ACHERAB9AALDH1A1ATM | |
| SCHEMBL1739332 | 0.86 | MAPT (0.46) | KMT2AEPHX1ACHERAB9ANPC1 | |
| SCHEMBL2475114 | 0.84 | MAPT (0.43) | KMT2AEPHX1ACHERAB9ANPC1 | |
| SCHEMBL9551099 | 0.82 | CTSB (0.40) | KMT2AMEN1CNR2MAPTSMN1; SMN2 | |
| SCHEMBL11603045 | 0.81 | CTSL (0.38) | CNR2ALDH1A1CTSLCTSBCTSS | |
| SCHEMBL7963422 | 0.81 | EPHX1 (0.43) | KMT2AEPHX1ACHERAB9ANPC1 | |
| SCHEMBL4661585 | 0.80 | RAB9A (0.37) | KMT2AMEN1EPHX1ACHERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024256574-A1 | PROCESS FOR PREPARING MACROCYCLIC BTK INHIBITORS | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024256568-A1 | SALT AND CRYSTAL FORMS OF A MACROCYCLIC BTK INHIBITOR | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024246287-A1 | MEDICAL USE OF A MACROCYCLIC REVERSIBLE BTK INHIBITOR | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2024-12-05 | — | — | WO | disclosed |
| EP-4448523-A1 | MACROCYCLIC BTK INHIBITORS | Crossfire Oncology Holding B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023110970-A1 | MACROCYCLIC BTK INHIBITORS | NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) | 2023-06-22 | — | — | WO | disclosed |
| EP-3464312-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | Celgene Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-01-08 | — | — | US | disclosed |
| US-10023558-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-07-17 | — | — | US | disclosed |
| US-20180009787-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-11 | — | — | US | disclosed |
| WO-2017210408-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION (US) | 2017-12-07 | — | — | WO | disclosed |
| WO-2016057370-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-04-14 | — | — | WO | disclosed |
| EP-2598486-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | Novartis AG (CH) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012013716-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | NOVARTIS AG (CH) | 2012-02-02 | — | — | WO | disclosed |
| EP-2389376-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2011-11-30 | — | — | EP | disclosed |
| WO-2008073982-A2 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| CN-101108878-A | Glp-1 analogues | SOD CONSEILS RECH APPLIC (FR) | 2008-01-23 | — | — | CN | disclosed |
| CN-100334109-C | Glucagon-like peptide-1 analogs | SOD CONSEILS RECH APPLIC (FR) | 2007-08-29 | — | — | CN | disclosed |
| CN-1342166-A | Glucagon-like peptide-1 analogs | SOD CONSEILS RECH APPLIC (FR) | 2002-03-27 | — | — | CN | disclosed |
| EP-0986551-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Pharmaceutical Company Limited (JP) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998054164-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023558-B2 | Compounds | SERPINB1, ELANE, MPO | KMT2A 3935/4885MEN1 3964/4885EPHX1 70/4885 |
| US-20180009787-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | KMT2A 4199/4885MEN1 4581/4885EPHX1 110/4885 |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | SERPINB1, ELANE, EPX | KMT2A 4207/4885MEN1 4112/4885EPHX1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.